Abstract
Among the proteases involved in the tumor invasion process, components of the plasminogen activator system (plasminogen activator type-urokinase uPA, its membrane receptor uPAR and its two inhibitors PAI-1 and PAI-2) appear to define high risk patients in primary breast cancer. As individual analysis of each component of the plasminogen activator system does not reflect the complex interactions between the different components, we studied the prognostic impact of a dissemination risk index combining the four variables. We found that this index was the most powerful prognostic factor, particularly in node-negative patients.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Biomarkers, Tumor / analysis*
-
Breast Neoplasms / chemistry*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / surgery
-
Female
-
Humans
-
Life Tables
-
Lymph Node Excision
-
Lymphatic Metastasis
-
Mastectomy
-
Middle Aged
-
Neoplasm Metastasis
-
Neoplasm Proteins / analysis
-
Neoplasm Proteins / blood
-
Plasminogen Activator Inhibitor 1 / analysis*
-
Plasminogen Activator Inhibitor 2 / analysis*
-
Prognosis
-
Receptors, Cell Surface / analysis*
-
Receptors, Estrogen / analysis
-
Receptors, Progesterone / analysis
-
Receptors, Urokinase Plasminogen Activator
-
Retrospective Studies
-
Risk
-
Severity of Illness Index*
-
Survival Analysis
-
Treatment Outcome
-
Urokinase-Type Plasminogen Activator / analysis*
Substances
-
Biomarkers, Tumor
-
Neoplasm Proteins
-
PLAUR protein, human
-
Plasminogen Activator Inhibitor 1
-
Plasminogen Activator Inhibitor 2
-
Receptors, Cell Surface
-
Receptors, Estrogen
-
Receptors, Progesterone
-
Receptors, Urokinase Plasminogen Activator
-
Urokinase-Type Plasminogen Activator